2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2748

Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study
Abstract Number: 1940

Immunologic Synovitis Score: A New Score for Synovial Membrane Characterization in Inflammatory and Non-Inflammatory Arthritis
Abstract Number: 2419

Immunomodulatory Effects of Bone-Marrow Mesenchymal Stem Cells in Rheumatoid Arthitis: Influence of Disease Activity
Abstract Number: 676

Immunosignature Autoantibody Profiles Provide Mechanistic Insight into Systemic Lupus Erythematosus and Differentiation from Symptomatically Overlapping Diseases
Abstract Number: 576

Immunosignature-Based Diagnosis and Prediction of Therapeutic Response Enables Retrospective Patient Stratification in a Phase IIa Clinical Trial for VAY736 in Primary Sjögren’s Syndrome
Abstract Number: 116

Immunotherapy-Induced Rheumatic Disease: How Prepared Are Rheumatologists to Address This Emerging Condition?
Abstract Number: 98

Impact of a Lung Ultrasound Course for Rheumatology Specialist (IMPACT-2)
Abstract Number: 908

Impact of a National Training Program on Primary Care Providers Utilization of Knee MRI
Abstract Number: 96

Impact of a Student Led Rheumatology Interest Group on Medical Student Interest in Rheumatology
Abstract Number: 1155

Impact of Adalimumab on Immunosuppressant Use in Patients with Active and Inactive Non-Infectious Intermediate, Posterior, or Pan-Uveitis in the Ongoing Open Label Study: Visual-III
Abstract Number: 1422

Impact of Adalimumab on Prednisone Use in Patients with Rheumatoid Arthritis in a Real World Setting – Results from the Corrona Registry
Abstract Number: 1470

Impact of Anti-Drug Antibody and Injection Site Reaction on Efficacy: 24-Week Results from a Phase III Study Comparing SB4 (etanercept biosimilar) with Reference Etanercept in Patients with Rheumatoid Arthritis
Abstract Number: 699

Impact of Anti-RBP Antibodies on Disease Activity and Quality-of-Life in Immunosuppressant Naive Systemic Lupus Erythematosus
Abstract Number: 108

Impact of Antiphospholipid Syndrome Ibook on Medical Students’ Improvement of Knowledge: An International Randomized Controlled Experimental Study
Abstract Number: 234

Impact of Arthritis Among Populations with Chronic Health Conditions in Rural Counties of the United States – 2015

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].